Interventional
Selective Chamber Angiography: This study is a development project for implementing a clinical imaging protocol involving a rotational X-ray acquisition of contrast filled cardiac chambers during a cardiac catheterization procedure. These 2-D rotational projection images will then be used to help develop, refine, and validate image processing techniques that will produce 3 and 4-D (3-D plus time) reconstructions of the cardiac chambers and implanted devices.
ACP: This study is a prospective, randomized, multicenter, active control to evaluate the safety and effectiveness of the ACP (Amplatzer Cardiac Plug) device in preventing thrombus from migrating from the left atrial appendage (LAA) in subjects who have non valvular atrial fibrillation, and is an alternative to long-term anticoagulation therapy.
TRILUMINATE: The objective of this trial is to evaluate the safety and effectiveness of the TriClipTM device in improving clinical outcomes in symptomatic patients with severe TR who have been determined by the site’s local heart team (consisting of one interventionalist, one cardiac surgeon, one heart failure specialist and one echocardiologist) to be at intermediate or greater estimated risk for mortality or morbidity with tricuspid valve surgery. This clinical investigation proposes to build on the current experience and attempts to fill an important clinical evidence gap for patients who continue to suffer from symptomatic TR despite medical therapy.
IONIS: The primary objective of this study is to evaluate the treatment effect of ION‑682884 on mortality and morbidity in a population of wild-type and hereditary ATTR-CM patients.
CARDIAMP: The purpose of this trial is to determine the safety and efficacy of CardiAMP cell therapy system in patients with post myocardial infarction heart failure.
Evolve MI: This study is being conducted to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management compared with routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction.
Atrium: This investigator-initiated randomized trial is being conducted to test whether abatacept, as compared to placebo, is associated with a reduction in MACE among participants who develop myocarditis after treatment with an ICI
EMBARK: This is a Phase 2a proof-of-concept study to assess safety, tolerability, and preliminary efficacy of mavacamten treatment on NT-proBNP levels and high-sensitivity cardiac troponin T (hs-cTnT) levels in participants with HFpEF and chronic elevation of cardiac biomarkers.
REBIRTH: The objective of REBIRTH is to determine the impact of bromocriptine therapy on myocardial recovery and subsequent clinical outcomes in a placebo controlled double blind randomized trial.
Spyral Affirm: The SPYRAL AFFIRM study is a multi-center, international, prospective, interventional, single arm study designed to study renal denervation in a real-world population with a focus on the safety, efficacy, and durability of the procedure in subjects with varying severity of hypertension and associated comorbidities
Evolut Expand II: This pivotal trial is intended to obtain high quality clinical evidence on the safety and effectiveness of the Medtronic Evolut PRO+ TAVR system in patients with moderate, symptomatic aortic stenosis.